secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000950170-23-057119
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q3 net loss narrows to $12.6M; revenue up 52% on YUTIQ royalty recognition
--------------------------------------------------------------------------------

- Total net revenue $15.2M (up 52% YoY) driven by $14.4M in royalties from YUTIQ sale.
- Net loss $12.6M ($0.33/share) vs $18.4M ($0.49/share); cash $136.0M at quarter end.
- EYP-1901 Phase 2 DAVIO 2 topline wet AMD data expected Dec 2023; PAVIA data Q2 2024.
- No drug-related SAEs in ongoing EYP-1901 trials; Phase 2 VERONA in DME to start Q1 2024.
- Leadership: George Elston promoted to EVP; Stuart Duty appointed to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023057119/0000950170-23-057119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023057119/eypt-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer